ABUS
Arbutus Biopharma
Arbutus Biopharma Corporation is a publicly traded (NASDAQ: ABUS) biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.It is headquartered in Vancouver, British Columbia and has research facilities in Warminster, Pennsylvania. The company was formerly known as Tekmira, which was spun out of Inex Pharmaceuticals in 2007.
Index: NASDAQ; Sector: Healthcare; Industry: Biotechnology & Drugs;
Marketcap: 254.86M; Volume: 227.00K; AvgVol 3m: 9.13M; Beta: 2.79;
Cost estimate:
P/E: –; EPS: -2.46; EPS growth quarter/prev quarter: 46.50%;
EPS growth this year: -137.80%; EPS growth past 5 years: -9.90%;
EPS ttm: -2.46;
P/S: 33.00; P/B: ; P/Cashflow: 03.08; P/FCF: ;
Sales: 7.68M; Sales growth quarter/prev quarter: 114.30%; Sales growth past 5 years: -16.70%;
Profitability:
Gross Margin: ; Profit Margin: ; Operating Margin: ;
ROA – return on assets: -138.80%; ROE – return on equity: 225.70%; LT Debt/Equity: ; Total Debt/Equity: ;
Dividend: –; Dividend Yield (%): –;
Insider Ownership: 1.70%; Insider Transactions:-1.40%;
Institutional Ownership: 34.90%; Institutional Transactions: 5.75%;
Data update: 07/10/2020.